Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2
Primary Purpose
Xerosis Cutis, Diabetes Mellitus, Type 2
Status
Unknown status
Phase
Phase 4
Locations
Indonesia
Study Type
Interventional
Intervention
Centella Asiatica Extract
Topical CA
Petroleum jelly
Sponsored by

About this trial
This is an interventional treatment trial for Xerosis Cutis focused on measuring dry skin, dm type 2, centella asiatica, superoxide dismutase, AGEs CML, IL-1α
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with Diabetes Mellitus Type 2
- <60 years old by the end of the study
- suffered from dry skin on lower leg skin area, (minimum score= 3, measured using SRRC)
- agree to not use any skin care product orally or topically on lower leg skin and any other drugs (unless its part of diabetes mellitus management)
- normal ankle brachial index value ranged from 0.91-1.3
Exclusion Criteria:
- the presence of diabetic ulcer on one of patient's foot
- the presence of infection or dermatitis on the experimented foot
- the presence of severe inflammation on the experimented skin (redness score >2 or/and fissure score >2 measured by SRRC or/and total SRRC score ranged from12-16)
- estimated glomerular filtration rate value (eGFR) < 45
- impaired liver function (increased by 2x from upper limit reference for AST/ALT)
Sites / Locations
- Universitas Indonesia
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Placebo Comparator
Experimental
Arm Label
Topical CA and Placebo Oral Drug
Petroleum Jelly and placebo oral drug
Centella asiatica extract and Topical CA
Arm Description
Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
Outcomes
Primary Outcome Measures
Change in Skin Capacitance
SCap measured in (AU)
Change in SOD
Superoxide Dismutase (compared to total protein)
Change in IL-1α
Interleukin-1α (compared to total protein)
Change in AGEs CML
Advanced Glycation End Product, N-(Carboxymethyl)lysine (compared to total protein)
Change in SRRC
Specified symptom sum score. Measuring dry skin using four variables (scale, roughness, redness, and cracking) in score ranged from 1 to 4 for each variable. The highest the value marks the driest skin
Secondary Outcome Measures
Full Information
NCT ID
NCT03815305
First Posted
January 18, 2019
Last Updated
January 20, 2019
Sponsor
Indonesia University
1. Study Identification
Unique Protocol Identification Number
NCT03815305
Brief Title
Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2
Official Title
Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2: a Study on N(6)-Carboxymethyl-lysine, Interleukin 1-α, Dan Superoxide Dismutase in Stratum Corneum
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 30, 2018 (Actual)
Primary Completion Date
January 12, 2019 (Actual)
Study Completion Date
June 30, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to evaluate the effect of Centella asiatica on hydration status of lower leg skin of DM type 2 patients by measuring SRRC and Skin Capacitance in correlation with AGEs CML, inflammation marker IL-1α, and oxidative stress SOD in stratum corneum.
Detailed Description
This ia a double blind randomized clinical trial on patients diagnosed with DM type 2 with dry skin to assess the effect of Centella asiatica (CA) on dry skin in corellation with AGEs CML, inflammation marker IL-1α, and oxidative stress SOD in stratum corneum after four weeks of treatment. Subjects are divided into three groups of treatment. The first group treated with oral CA and topical CA, second group treated with oral placebo and topical CA, and the last group treated with oral and topical placebo. The total subjects in each treatment groups are 53 subjects. The recruited subjects will be randomized to receive three different treatments, consist of 1. First group (A) will receive combination of oral CA at 2x1100 mg dose and 1% topical CA ointment. 2. Second group (B) will receive oral placebo and topical CA 1% ointment 3. Third group (C) will receive oral placebo and petroleum jelly as topical placebo The recruited subjects will still receive the prescribed treatment for DM type 2. The treatment for dry skin will be administered for 28 days. Randomization done by our supervisor using computer program (RandlistR) by assigning code number for each subjects. The procedures of treatment administration are explained below: 1. Every subject will receive 56 capsules and 10 gram of ointment to be used in 2 weeks period. Subjects will also receive explanation on how to take the drugs 2. Oral drug are taken 2 capsules (@ 550 mg) b.i.d over 12 hours. 3. The ointment is applied two times a day 15 minutes after bath time. 4. The application have to be distributed evenly on a specific 7 x 20 cms area on lower leg. All patients will be given plastic cover to determine the area. 5. The estimation of ointment applied on every leg is as much as ½ FTU or about 0,25 gram. 6. After 2 week period ended, subject will be given the same treatment at follow-up visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Xerosis Cutis, Diabetes Mellitus, Type 2
Keywords
dry skin, dm type 2, centella asiatica, superoxide dismutase, AGEs CML, IL-1α
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
159 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Topical CA and Placebo Oral Drug
Arm Type
Active Comparator
Arm Description
Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
Arm Title
Petroleum Jelly and placebo oral drug
Arm Type
Placebo Comparator
Arm Description
Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
Arm Title
Centella asiatica extract and Topical CA
Arm Type
Experimental
Arm Description
Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
Intervention Type
Drug
Intervention Name(s)
Centella Asiatica Extract
Other Intervention Name(s)
Oral CA
Intervention Description
centlla asiatica oral drug at 1100 mg dose
Intervention Type
Drug
Intervention Name(s)
Topical CA
Other Intervention Name(s)
Centella asiatica ointment
Intervention Description
1% centella asiatica ointment
Intervention Type
Drug
Intervention Name(s)
Petroleum jelly
Other Intervention Name(s)
Topical Placebo
Intervention Description
vaseline album
Primary Outcome Measure Information:
Title
Change in Skin Capacitance
Description
SCap measured in (AU)
Time Frame
1 month (evaluated every 2 weeks)
Title
Change in SOD
Description
Superoxide Dismutase (compared to total protein)
Time Frame
1 month (evaluated every 2 weeks)
Title
Change in IL-1α
Description
Interleukin-1α (compared to total protein)
Time Frame
1 month (evaluated every 2 weeks)
Title
Change in AGEs CML
Description
Advanced Glycation End Product, N-(Carboxymethyl)lysine (compared to total protein)
Time Frame
1 month (evaluated every 2 week)
Title
Change in SRRC
Description
Specified symptom sum score. Measuring dry skin using four variables (scale, roughness, redness, and cracking) in score ranged from 1 to 4 for each variable. The highest the value marks the driest skin
Time Frame
1 month (evaluated every 2 week)
10. Eligibility
Sex
All
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with Diabetes Mellitus Type 2
<60 years old by the end of the study
suffered from dry skin on lower leg skin area, (minimum score= 3, measured using SRRC)
agree to not use any skin care product orally or topically on lower leg skin and any other drugs (unless its part of diabetes mellitus management)
normal ankle brachial index value ranged from 0.91-1.3
Exclusion Criteria:
the presence of diabetic ulcer on one of patient's foot
the presence of infection or dermatitis on the experimented foot
the presence of severe inflammation on the experimented skin (redness score >2 or/and fissure score >2 measured by SRRC or/and total SRRC score ranged from12-16)
estimated glomerular filtration rate value (eGFR) < 45
impaired liver function (increased by 2x from upper limit reference for AST/ALT)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suhendro Suhendro, Doctor
Organizational Affiliation
Indonesia University
Official's Role
Study Chair
Facility Information:
Facility Name
Universitas Indonesia
City
Jakarta Pusat
State/Province
Jakarta
ZIP/Postal Code
10430
Country
Indonesia
12. IPD Sharing Statement
Learn more about this trial
Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2
We'll reach out to this number within 24 hrs